Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus DECADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus DECADERM.
ANUSOL HC vs DECADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid